Last reviewed 2026-04-23 · How we verify

Eribulin standard regimen

Eribulin is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.

Eribulin is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Liposarcoma, Other solid tumors (in clinical development).

At a glance

Mechanism of action

Eribulin is a non-taxane microtubule inhibitor derived from halichondrin B. It binds to the plus end of microtubules and inhibits their growth and dynamics, causing G2/M phase cell cycle arrest. This mechanism leads to apoptosis in rapidly dividing cancer cells, particularly in breast cancer and other solid tumors.

Approved indications

• Metastatic breast cancer
• Liposarcoma
• Other solid tumors (in clinical development)

Common side effects

• Neutropenia
• Peripheral neuropathy
• Fatigue
• Nausea
• Alopecia
• Anemia
• Febrile neutropenia

Key clinical trials

• Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer (PHASE3)
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
• Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (PHASE3)
• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (PHASE3)
• Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.